What is thalassaemia?

Thalassaemia is an inherited blood disorder that occurs when the body does not produce enough haemoglobin, a protein responsible for carrying oxygen. When this protein is lacking, the red blood cells do not function properly, and fewer healthy red blood cells travel in the bloodstream. This causes insufficient oxygen to be delivered to the other cells, leading to fatigue, weakness, and shortness of breath, which is a medical condition called anaemia.^1,2

There are different types of thalassaemia and each type and severity might be associated with different symptoms. However, the most common symptoms of thalassaemia are fatigue, weakness, pale skin, facial bone deformities, slow growth, abdominal swelling and dark urine.³

Thalassaemia can cause complications, including iron overload. People with this condition can have too much iron in their bodies, which can damage their hearts, livers, and endocrine systems. Furthermore, they are at an increased risk of infections. Severe cases of thalassaemia might cause bone deformities, as this condition leads to bone marrow expansion and an enlarged spleen.³

Even though thalassaemia is globally prevalent, it affects populations in the Mediterranean, Middle East, Southeast, Asia and Africa differently.⁴ The risk factors include a family history of thalassaemia and certain ancestry, i.e. thalassaemia occurs most often in African Americans and people of Mediterranean and Southeast Asian descent.³

Importance of thalassaemia to public health

Thalassaemia has a significant impact on patients and their families. People with thalassaemia may require lifelong medical treatment, including regular blood transfusions, iron chelation therapy, and potential bone marrow transplants.⁵

In addition to the personal, and human impact, the social and economic burden of thalassaemia can be substantial due to the healthcare costs and loss of productivity.⁶

Given the personal and societal impacts of thalassaemia, effective public health initiatives and awareness campaigns are important. These initiatives aim to prevent thalassaemia, improve early diagnosis and effective treatments, and increase the quality of life for individuals with this condition⁷.

Public health initiatives

Several public health initiatives are crucial in addressing the challenges of thalassaemia. These initiatives include:

Prenatal screening and genetic counselling 

This initiative involves testing pregnant people to determine if their baby is affected by thalassaemia.⁸ Commonly, this includes testing the pregnant parent’s blood and in some cases, chorionic villus sampling or amniocentesis.⁹ With these tests, it is possible to detect thalassaemia early, which allows timely interventions and informed decision-making from the parent's side.¹⁰ On the other side, genetic counselling is crucial to explain the importance of the screening as well as the interpretation of its results. This counselling is also important to discuss available options such as prenatal detection of thalassaemia and foetal therapy. Finally, it is important to provide emotional support to families.¹¹

Carrier screening programs

These types of programs are intended to identify people who carry one copy of the thalassaemia gene but do not have the symptoms themselves. This information can be very important for couples as it helps them understand their risk of having a child with thalassaemia. Carrier screening can be offered to individuals from populations with a high prevalence of thalassaemia, as well as to couples planning to have a baby. Carrier screening programs should be implemented with careful consideration of ethical and social implications, ensuring informed consent and maintaining the confidentiality of genetic information.¹²

Premarital screening 

Premarital screening involves testing prospective spouses for thalassaemia carrier status before marriage.¹³ This can help couples make informed decisions about family planning and it might help to reduce the risk of having affected children.¹⁴ If both partners are carriers, they can explore options such as prenatal diagnosis, preimplantation genetic diagnosis, or adoption.¹⁵ Premarital screening programs must be implemented with sensitivity to cultural and religious beliefs, ensuring respect for individual autonomy and reproductive rights.¹⁶

Newborn screening 

Newborn screening programs are important to identify children with thalassaemia shortly after their birth, helping the early initiation of treatment and improving long-term outcomes, if necessary. Early diagnosis allows for the timely beginning of appropriate medical management, such as regular blood transfusions and iron chelation therapy, which can significantly improve the quality of life for individuals with thalassaemia. Newborn screening programs may have limitations in terms of sensitivity and specificity, and access to appropriate follow-up care may vary across different regions.¹⁷

Awareness campaigns

Raising public awareness about thalassaemia is critical for successful prevention and management of this condition.¹⁸ With that being said, effective awareness campaigns include:  

Increasing public knowledge

By communicating correct and accessible information about thalassaemia through various channels, including traditional media, social media, and community outreach programs, awareness campaigns can educate the population about the causes, symptoms, and available treatment options.¹⁹  

Addressing stigma and discrimination

Individuals with thalassaemia may face stigma and discrimination due to misconceptions and lack of understanding.²⁰ Awareness campaigns can play a crucial role in challenging these stereotypes, promoting acceptance and inclusion, and fostering a more supportive environment for individuals with thalassaemia.²¹ 

Empowering individuals and families

By providing, improving, and promoting access to support groups, peer-to-peer networks, and relevant resources, awareness campaigns can empower individuals and families affected by thalassaemia to manage their condition effectively and improve their quality of life.²²

Challenges and future directions

Despite significant progress in thalassaemia research and management, several challenges remain. Firstly, there are disparities in access to health care as access to quality diagnosis, treatment, and support services for thalassaemia varies significantly across different regions and socioeconomic groups.²³ Addressing these disparities requires a multi-pronged approach that includes strengthening healthcare systems, improving access to affordable medications, and ensuring equitable distribution of resources.

It is also important to point out the development of innovative strategies. Continued research and development are crucial for improving the prevention and management of thalassaemia. This includes exploring strategies such as gene editing technologies, developing more effective and targeted therapies, and utilising technology for improved outreach and education.²⁴

Finally, international collaboration is essential for sharing best practices, pooling resources, and accelerating research and development efforts in thalassaemia.²⁵ By fostering partnerships between researchers, clinicians, and policymakers across different countries, we can collectively address the global burden of this disease.

Summary

Thalassaemia is a group of inherited blood disorders that affect haemoglobin production. This article discusses the importance of public health initiatives and awareness campaigns in addressing the challenges posed by thalassaemia. Key public health initiatives include prenatal screening, carrier screening, premarital screening, and newborn screening programs. Awareness campaigns play a crucial role in increasing public knowledge, addressing stigma, and empowering individuals and families affected by thalassaemia. The article also highlights the challenges and future directions for thalassaemia research and management, emphasising the need for continued research, innovation, and global collaboration.

FAQs

What is thalassaemia?

Thalassaemia is a group of inherited blood disorders characterised by reduced or absent production of haemoglobin, the protein in red blood cells that carries oxygen.  

What are the symptoms of thalassaemia?

Symptoms of thalassaemia can vary depending on the severity of the condition and may include fatigue, weakness, pale skin, shortness of breath, and an enlarged spleen.

How is thalassaemia diagnosed?

Diagnosis of thalassaemia typically involves blood tests, such as a complete blood count and haemoglobin electrophoresis.

What are the treatment options for thalassaemia?

Treatment options for thalassaemia may include regular blood transfusions, iron chelation therapy, and in some cases, bone marrow transplantation.

What are the benefits of prenatal screening for thalassaemia?

Prenatal screening allows for early detection of thalassaemia in foetuses, enabling parents to make informed decisions about pregnancy and family planning.

How can I reduce my risk of having a child with thalassaemia?

If you or your partner have a family history of thalassaemia, consider genetic counselling and carrier screening to assess your risk.

What is the role of awareness campaigns in addressing thalassaemia?

Awareness campaigns can increase public knowledge about thalassaemia, reduce stigma, and empower individuals and families affected by the condition.

What are the future directions for thalassaemia research?

Future directions for thalassaemia research include exploring innovative therapies such as gene editing technologies and strengthening global collaboration to accelerate research efforts.

References

1. CDC. Thalassemia. 2024 [citado 23 de dezembro de 2024]. About thalassemia. Disponível em: https://www.cdc.gov/thalassemia/about/index.html
2. nhs.uk [Internet]. 2017 [citado 23 de dezembro de 2024]. Thalassaemia. Disponível em: https://www.nhs.uk/conditions/thalassaemia/
3. Mayo Clinic [Internet]. [citado 23 de dezembro de 2024]. Thalassemia-thalassemia - symptoms & causes. Disponível em: https://www.mayoclinic.org/diseases-conditions/thalassemia/symptoms-causes/syc-20354995
4. Weatherall, D. J., & Clegg, J. B. (2001). The thalassemia syndromes. Blackwell Science.
5. nhs.uk [Internet]. 2017 [citado 23 de dezembro de 2024]. Thalassaemia - treatment. Disponível em: https://www.nhs.uk/conditions/thalassaemia/treatment/
6. Aydinok Y, Purushotham S, Yucel A, Glassberg M, Deshpande S, Potrata B, et al. Systematic literature review of the indirect costs and humanistic burden of β-thalassemia. Therapeutic Advances in Hematology [Internet]. janeiro de 2024 [citado 23 de dezembro de 2024];15:20406207241270872. Disponível em: https://journals.sagepub.com/doi/10.1177/20406207241270872
7. Simplified L. Timely detection and prevention key to combating thalassemia - legality simplified [Internet]. 2024 [citado 23 de dezembro de 2024]. Disponível em: https://www.legalitysimplified.com/timely-detection-and-prevention-key-to-combating-thalassemia/
8. Suwannakhon N, Hemvuthiphan J, Pangeson T, Mahingsa K, Pingyod A, Bumrungpakdee W, et al. Non-invasive prenatal screening & diagnosis of β-thalassaemia in an affected foetus. Indian J Med Res [Internet]. maio de 2023 [citado 30 de dezembro de 2024];157(5):447–52. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443724/
9. Mensah C, Sheth S. Optimal strategies for carrier screening and prenatal diagnosis of α- and β-thalassemia. Hematology Am Soc Hematol Educ Program [Internet]. 10 de dezembro de 2021 [citado 30 de dezembro de 2024];2021(1):607–13. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791174/
10. nhs.uk [Internet]. 2020 [citado 30 de dezembro de 2024]. Screening for sickle cell and thalassaemia. Disponível em: https://www.nhs.uk/pregnancy/your-pregnancy-care/screening-for-sickle-cell-and-thalassaemia/
11. The importance of genetic counselling in sickle cell and thalassemia screening – PHE Screening [Internet]. 2020 [citado 30 de dezembro de 2024]. Disponível em: https://phescreening.blog.gov.uk/2020/02/19/sct-genetic-counselling/ 
12. Modell, B., & Darlison, M. (2008). Thalassemia. The Lancet, 371(9616), 1541-1551.
13. Hashemizadeh H, Noori R. Premarital screening of beta thalassemia minor in north-east of iran. Iran J Ped Hematol Oncol [Internet]. 2013 [citado 30 de dezembro de 2024];3(1):210–5. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915444/
14. Hussein N, Henneman L, Kai J, Qureshi N. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay‐Sachs disease. Cochrane Database Syst Rev [Internet]. 11 de outubro de 2021 [citado 30 de dezembro de 2024];2021(10):CD010849. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504980/
15. GOV.UK [Internet]. [citado 30 de dezembro de 2024]. Information and choices for women and couples at risk of having a baby with thalassaemia major. Disponível em: https://www.gov.uk/government/publications/baby-at-risk-of-having-thalassaemia-description-in-brief/information-and-choices-for-women-and-couples-at-risk-of-having-a-child-with-thalassaemia-major
16. Suresh H, Jamil S, Padhi BK, Hossain MdJ. Thalassemia prevention: Religious and cultural barriers to premarital screening in Bangladesh. Health Sci Rep [Internet]. 5 de abril de 2023 [citado 30 de dezembro de 2024];6(4):e1176. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075244/
17. Bender MA, Hulihan M, Dorley MC, Aguinaga M del P, Ojodu J, Yusuf C. Newborn screening practices for beta-thalassemia in the united states. Int J Neonatal Screen [Internet]. 13 de dezembro de 2021 [citado 30 de dezembro de 2024];7(4):83. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703506/
18. Hossain MS, Hasan MdM, Raheem E, Islam MS, Al Mosabbir A, Petrou M, et al. Lack of knowledge and misperceptions about thalassaemia among college students in Bangladesh: a cross-sectional baseline study. Orphanet J Rare Dis [Internet]. 21 de fevereiro de 2020 [citado 30 de dezembro de 2024];15:54. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035777/
19. REPSOL [Internet]. [citado 30 de dezembro de 2024]. Thalassemia awareness programs in Malaysia. Disponível em: https://www.repsol.com/en/sustainability/sustainability-strategy/our-contribution-to-the-sdgs/repsol-sdg-success-stories/thalassemia-awareness-programs/index.cshtml
20. Kumar N, Turbitt E, Biesecker BB, Miller IM, Cham B, Smith KC, et al. Managing the need to tell: Triggers and strategic disclosure of thalassemia major in Singapore. Am J Med Genet A [Internet]. maio de 2019 [citado 30 de dezembro de 2024];179(5):762–9. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467747/
21. Frequently asked question’s (FAQ’s) | persons with disabilities welfare department maharashtra | india [Internet]. [citado 30 de dezembro de 2024]. Disponível em: https://divyangkalyan.maharashtra.gov.in/frequently-asked-questions-faqs/
22. World Thalassemia Day: Creating awareness: Empowering communities, saving lives. The Times of India [Internet]. 8 de maio de 2024 [citado 30 de dezembro de 2024]; Disponível em: https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/world-thalassemia-day-creating-awareness-empowering-communities-saving-lives/articleshow/109927324.cms
23. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood [Internet]. 29 de setembro de 2011 [citado 30 de dezembro de 2024];118(13):3479–88. Disponível em: https://ashpublications.org/blood/article/118/13/3479/29247/How-I-treat-thalassemia
24. Cristea, S., Urdea, M., Scarciol, P., & Iliescu, R. (2017). Gene editing technologies in thalassemia. Journal of Medicine and Life, 10(2), 118-124.
25. للمرضي [Internet]. TIF. [citado 30 de dezembro de 2024]. Disponível em: https://thalassaemia.org.cy/ar/patients/